Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
As of Jan. 10, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2025年1月10日，醫療保健板塊的兩隻股票可能正在向重視動量作爲交易決策關鍵標準的投資者發出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
相對強弱指數（RSI）是一種動量指標，它將股票在價格上漲時的強度與價格下跌時的強度進行比較。與股票價格走勢相比，它可以讓交易者更好地了解一隻股票在短期內的表現。根據Benzinga Pro的說法，當RSI高於70時，資產通常被視爲超買。
Here's the latest list of major overbought players in this sector.
以下是該板塊最新的主要超買股票名單。
Sana Biotechnology Inc (NASDAQ:SANA)
薩那生物技術公司（納斯達克：SANA）
- On Tuesday, Sana Biotechnology released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a type 1 diabetes patient without the use of any immunosuppression. The study was conducted in partnership with Uppsala University Hospital. The company's stock surged around 162% over the past five days and has a 52-week high of $12.00.
- RSI Value: 73.4
- SANA Price Action: Shares of Sana Biotechnology closed at $4.30 on Wednesday.
- 週二，薩那生物技術發佈了首次人體研究的初步結果，該研究將UP421（利用薩那的低免疫（HIP）科技工程化的同種異體胰島電芯治療）移植到一名未使用任何免疫抑制劑的1型糖尿病患者身上。該研究是與烏普薩拉大學醫院合作進行的。公司的股票在過去五天中暴漲約162%，並且創下了$12.00的52周高點。
- 相對強弱指數：73.4
- SANA價格走勢：薩那生物技術的股票在週三收於$4.30。
Mesoblast Ltd (NASDAQ:MESO)
Mesoblast有限公司（納斯達克：MESO）
- On Dec. 19, Mesoblast announced the U.S. Food and Drug Administration (FDA) approved Ryoncil. Ryoncil is the first FDA approved therapy for children aged 2 months and older with steroid-refractory acute graft versus host disease (SR-aGvHD).. The company's stock gained around 53% over the past month and has a 52-week high of $22.00.
- RSI Value: 77.8
- MESO Price Action: Shares of Mesoblast fell 4% to close at $17.18 on Wednesday.
- 在12月19日，Mesoblast宣佈美國食品藥品監督管理局（FDA）批准了Ryoncil。Ryoncil是FDA批准的第一種針對2個月及以上兒童的類固醇難治性急性移植物抗宿主病（SR-aGvHD）的治療藥物。該公司的股票在過去一個月上漲了約53%，目前52周高點爲22.00美元。
- RSI值：77.8
- MESO價格走勢：Mesoblast的股票在週三下跌了4%，收於17.18美元。
Read This Next:
接下來請閱讀：
- How To Earn $500 A Month From Synovus Financial Stock Ahead Of Q4 Earnings
- 如何在第四季度業績前，從西諾烏斯金融股票中賺取每月500美元
譯文內容由第三人軟體翻譯。
